QuidelOrtho and Lifotronic agree on global immunoassay portfolio expansion

QuidelOrtho has signed a strategical proviso statement with Lifotronic Technology for expanding its planetary immunoassay portfolio, focusing connected expediting entree to high-throughput and low-to-mid measurement immunoassay analysers.

The concern aims to bring quality, cost-efficient, and scalable diagnostic solutions to selected planetary markets extracurricular the US.

The immunoassay proviso statement is expected to heighten QuidelOrtho’s quality to vie successful caller regions.

It provides the institution with entree to respective analysers supported by an extended paper of assays, covering some regular and speciality testing.

The concern volition present implicit 25 caller assays that are not offered connected QuidelOrtho’s VITROS system, bringing the full fig of disposable assays connected these caller platforms to much than 70.

These developments are intended to alteration QuidelOrtho to fulfil broader tender requirements and code the needs of assorted laboratory environments.

Laboratories ranging from those requiring low-volume solutions to larger settings needing scalable capableness and broad trial menus basal to payment from this expanded offering.

The inaugural volition assistance code paper gaps and amended competitiveness successful planetary tenders by offering laboratories much flexible strategy options.

QuidelOrtho's planetary objective laboratory and transfusion medicine elder vice-president Bryan Hanson said: “Through our collaboration with Lifotronic Technology, QuidelOrtho volition rapidly present scalable investigating solutions that further beforehand our semipermanent innovation strategy successful halfway maturation markets.

“This statement strengthens our portfolio successful markets wherever assay breadth and outgo ratio are cardinal requirements, portion offering customers a broader and much divers acceptable of solutions.”

In March 2024, QuidelOrtho announced that Health Canada had approved its Triage placental maturation origin (PIGF) trial for in-lab use.

"QuidelOrtho and Lifotronic hold connected planetary immunoassay portfolio expansion" was primitively created and published by Medical Device Network, a GlobalData owned brand.

The accusation connected this tract has been included successful bully religion for wide informational purposes only. It is not intended to magnitude to proposal connected which you should rely, and we springiness nary representation, warranty oregon guarantee, whether explicit oregon implied arsenic to its accuracy oregon completeness. You indispensable get nonrecreational oregon specializer proposal earlier taking, oregon refraining from, immoderate enactment connected the ground of the contented connected our site.